OptimizeRx (NASDAQ:OPRX) Given “Buy” Rating at B. Riley Financial

OptimizeRx (NASDAQ:OPRX)‘s stock had its “buy” rating restated by analysts at B. Riley Financial in a research report issued on Friday,Benzinga reports. They currently have a $11.00 price objective on the stock, down from their prior price objective of $28.00. B. Riley Financial’s price target suggests a potential upside of 78.28% from the stock’s current price.

Other equities analysts have also issued research reports about the company. Citizens Jmp lifted their price target on OptimizeRx from $23.00 to $24.00 and gave the company a “market outperform” rating in a research note on Friday, November 7th. Wall Street Zen raised OptimizeRx from a “buy” rating to a “strong-buy” rating in a research note on Sunday, December 14th. Zacks Research downgraded OptimizeRx from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 15th. Stifel Nicolaus dropped their target price on shares of OptimizeRx from $21.00 to $17.00 and set a “buy” rating for the company in a report on Friday. Finally, Stephens reduced their price target on shares of OptimizeRx from $17.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Friday. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.00.

OptimizeRx Price Performance

Shares of NASDAQ:OPRX traded down $1.36 during midday trading on Friday, hitting $6.17. The stock had a trading volume of 949,598 shares, compared to its average volume of 379,532. The company’s 50-day moving average price is $10.63 and its 200-day moving average price is $14.80. OptimizeRx has a fifty-two week low of $3.99 and a fifty-two week high of $22.25. The company has a quick ratio of 3.05, a current ratio of 3.05 and a debt-to-equity ratio of 0.20. The company has a market capitalization of $115.01 million, a P/E ratio of 19.67 and a beta of 1.20.

OptimizeRx (NASDAQ:OPRX) last announced its quarterly earnings data on Saturday, January 31st. The company reported $0.51 earnings per share (EPS) for the quarter. OptimizeRx had a net margin of 0.03% and a return on equity of 6.37%. As a group, equities research analysts predict that OptimizeRx will post -0.33 EPS for the current fiscal year.

OptimizeRx announced that its Board of Directors has approved a share buyback plan on Thursday, March 5th that permits the company to buyback $10.00 million in outstanding shares. This buyback authorization permits the company to repurchase up to 6.8% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s management believes its stock is undervalued.

Institutional Investors Weigh In On OptimizeRx

A number of institutional investors have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC increased its position in OptimizeRx by 600.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,121 shares of the company’s stock valued at $29,000 after acquiring an additional 1,818 shares during the period. Quantbot Technologies LP bought a new stake in shares of OptimizeRx in the second quarter worth $44,000. BNP Paribas Financial Markets increased its holdings in OptimizeRx by 119.2% in the second quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock valued at $55,000 after purchasing an additional 2,215 shares during the period. State of Alaska Department of Revenue bought a new position in OptimizeRx during the 4th quarter worth $62,000. Finally, USA Financial Formulas bought a new position in OptimizeRx during the 3rd quarter worth $131,000. 76.47% of the stock is owned by institutional investors.

More OptimizeRx News

Here are the key news stories impacting OptimizeRx this week:

• Positive Sentiment: Q4 results topped estimates — OPRX reported $0.51 EPS and $32.24M in revenue, beating consensus and highlighting continued revenue growth. This is the fundamental positive underpinning the shares. GlobeNewswire: Press Release
• Positive Sentiment: Board authorized a $10.0M share repurchase (up to ~6.8% of shares), a signal management views the stock as undervalued and a potential support for the share price. RTT News: Buyback
• Neutral Sentiment: Company-hosted earnings call and multiple transcripts are available for investors to assess management commentary and execution plans; useful for judging sustainability of growth and margin outlook. Yahoo Finance: Earnings Highlights
• Neutral Sentiment: Trading experienced repeated LULD pauses (multiple intraday halts) — this indicates elevated volatility and may have contributed to larger intraday moves and volume. (Market notices reported multiple LULD pauses.)
• Negative Sentiment: FY‑2026 revenue guidance of $109M–$114M came in materially below the consensus (~$122M), creating the primary negative catalyst pushing the stock lower as investors reprice forward growth expectations. Seeking Alpha: Guidance
• Negative Sentiment: Stephens cut its price target from $17 to $10 and moved to an “equal weight” rating, sending a clear signal to investors and likely amplifying selling pressure from analysts/quant strategies. Benzinga: Analyst Note

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.